AstraZeneca hit by falling Crestor sales, higher costs

LONDON (Reuters) – Generic competition to cholesterol fighter Crestor and higher costs hit AstraZeneca in the first quarter, despite good sales of new drugs, but the group said on Friday it remained on track for a promised return to sales growth in 2018.

Source: Reuters Feed

(Visited 1 times, 1 visits today)

RSS Feed

Just a chill little widget delivery boy. =)

Leave a Reply

Your email address will not be published. Required fields are marked *